173 related articles for article (PubMed ID: 37794795)
1. Susceptibility of pediatric acute lymphoblastic leukemia to STAT3 inhibition depends on p53 induction.
Gasparoli L; Virely C; Tsakaneli A; Che N; Edwards D; Bartram J; Hubank M; Pal D; Heidenreich O; Martens JHA; De Boer J; Williams O
Haematologica; 2024 Apr; 109(4):1069-1081. PubMed ID: 37794795
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibition sensitizes p53-deficient B-cell precursor acute lymphoblastic leukemia to chemotherapy.
Cox WPJ; Evander N; Van Ingen Schenau DS; Stoll GR; Anderson N; De Groot L; Grünewald KJT; Hagelaar R; Butler M; Kuiper RP; Van der Meer LT; Van Leeuwen FN
Haematologica; 2024 Jun; 109(6):1755-1765. PubMed ID: 38124624
[TBL] [Abstract][Full Text] [Related]
3. Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type
Wang X; Yamamoto Y; Imanishi M; Zhang X; Sato M; Sugaya A; Hirose M; Endo S; Natori Y; Moriwaki T; Yamato K; Hyodo I
Oncol Lett; 2021 Jul; 22(1):558. PubMed ID: 34084225
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia.
Demir S; Boldrin E; Sun Q; Hampp S; Tausch E; Eckert C; Ebinger M; Handgretinger R; Kronnie GT; Wiesmüller L; Stilgenbauer S; Selivanova G; Debatin KM; Meyer LH
Haematologica; 2020 Jan; 105(1):170-181. PubMed ID: 31073076
[TBL] [Abstract][Full Text] [Related]
5. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
Andreeff M; Kelly KR; Yee K; Assouline S; Strair R; Popplewell L; Bowen D; Martinelli G; Drummond MW; Vyas P; Kirschbaum M; Iyer SP; Ruvolo V; González GM; Huang X; Chen G; Graves B; Blotner S; Bridge P; Jukofsky L; Middleton S; Reckner M; Rueger R; Zhi J; Nichols G; Kojima K
Clin Cancer Res; 2016 Feb; 22(4):868-76. PubMed ID: 26459177
[TBL] [Abstract][Full Text] [Related]
6. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia.
Zhou M; Gu L; Abshire TC; Homans A; Billett AL; Yeager AM; Findley HW
Leukemia; 2000 Jan; 14(1):61-7. PubMed ID: 10637478
[TBL] [Abstract][Full Text] [Related]
7. Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
Bell HL; Blair HJ; Singh M; Moorman AV; Heidenreich O; van Delft FW; Lunec J; Irving JAE
Cancer Cell Int; 2023 Sep; 23(1):202. PubMed ID: 37715172
[TBL] [Abstract][Full Text] [Related]
8. MDM2- and FLT3-inhibitors in the treatment of
Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
[TBL] [Abstract][Full Text] [Related]
9. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
[TBL] [Abstract][Full Text] [Related]
10. Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1-driven B-cell precursor acute lymphoblastic leukemia.
Polak R; Bierings MB; van der Leije CS; Sanders MA; Roovers O; Marchante JRM; Boer JM; Cornelissen JJ; Pieters R; den Boer ML; Buitenhuis M
Haematologica; 2019 Apr; 104(4):738-748. PubMed ID: 30381299
[TBL] [Abstract][Full Text] [Related]
11. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf
Chapeau EA; Gembarska A; Durand EY; Mandon E; Estadieu C; Romanet V; Wiesmann M; Tiedt R; Lehar J; de Weck A; Rad R; Barys L; Jeay S; Ferretti S; Kauffmann A; Sutter E; Grevot A; Moulin P; Murakami M; Sellers WR; Hofmann F; Jensen MR
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3151-3156. PubMed ID: 28265066
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of esophageal-carcinoma cell proliferation by genistein via suppression of JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways.
Gao J; Xia R; Chen J; Gao J; Luo X; Ke C; Ren C; Li J; Mi Y
Aging (Albany NY); 2020 Apr; 12(7):6240-6259. PubMed ID: 32276266
[TBL] [Abstract][Full Text] [Related]
13. The Landscape of Secondary Genetic Rearrangements in Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia with t(12;21).
Kaczmarska A; Derebas J; Pinkosz M; Niedźwiecki M; Lejman M
Cells; 2023 Jan; 12(3):. PubMed ID: 36766699
[TBL] [Abstract][Full Text] [Related]
14. Association Analysis of TP53 rs1042522, MDM2 rs2279744, rs3730485, MDM4 rs4245739 Variants and Acute Myeloid Leukemia Susceptibility, Risk Stratification Scores, and Clinical Features: An Exploratory Study.
Tripon F; Iancu M; Trifa A; Crauciuc GA; Boglis A; Balla B; Cosma A; Dima D; Candea M; Lazar E; Jimbu L; Banescu C
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492903
[TBL] [Abstract][Full Text] [Related]
15. SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric
Serafin V; Porcù E; Cortese G; Mariotto E; Veltri G; Bresolin S; Basso G; Accordi B
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817853
[TBL] [Abstract][Full Text] [Related]
16. RAG1 co-expression signature identifies ETV6-RUNX1-like B-cell precursor acute lymphoblastic leukemia in children.
Chen D; Camponeschi A; Nordlund J; Marincevic-Zuniga Y; Abrahamsson J; Lönnerholm G; Fogelstrand L; Mårtensson IL
Cancer Med; 2021 Jun; 10(12):3997-4003. PubMed ID: 33987955
[TBL] [Abstract][Full Text] [Related]
17. Association between Dysfunction of the Nucleolar Stress Response and Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia.
Nakagawa S; Kawahara K; Okamoto Y; Kodama Y; Nishikawa T; Kawano Y; Furukawa T
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291909
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
Usami I; Imamura T; Takahashi Y; Suenobu SI; Hasegawa D; Hashii Y; Deguchi T; Hori T; Shimada A; Kato K; Ito E; Moriya-Saito A; Kawasaki H; Hori H; Yumura-Yagi K; Hara J; Sato A; Horibe K;
Int J Hematol; 2019 Apr; 109(4):477-482. PubMed ID: 30689137
[TBL] [Abstract][Full Text] [Related]
19. The MDM4/MDM2-p53-IGF1 axis controls axonal regeneration, sprouting and functional recovery after CNS injury.
Joshi Y; Sória MG; Quadrato G; Inak G; Zhou L; Hervera A; Rathore KI; Elnaggar M; Cucchiarini M; Marine JC; Puttagunta R; Di Giovanni S
Brain; 2015 Jul; 138(Pt 7):1843-62. PubMed ID: 25981963
[TBL] [Abstract][Full Text] [Related]
20. RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia.
Sharma G; Tran TM; Bansal I; Beg MS; Bhardwaj R; Bassi J; Tan Y; Jaiswal AK; Tso C; Jain A; Singh J; Chattopadhyay P; Singh A; Chopra A; Bakhshi S; Casero D; Rao DS; Palanichamy JK
J Exp Clin Cancer Res; 2023 Sep; 42(1):231. PubMed ID: 37670323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
